Intellia Therapeutics, Inc. (NTLA) saw its loss widen to $10.56 million, or $0.31 a share for the quarter ended Dec. 31, 2016. In the previous year period, the company reported a loss of $5.24 million, or $9.57 a share.
Revenue during the quarter surged 232.37 percent to $5.63 million from $1.69 million in the previous year period.
Operating loss for the quarter was $10.82 million, compared with an operating loss of $5.49 million in the previous year period.
"2016 was a phenomenal year for Intellia. We signed a multi-year research and development collaboration with Regeneron Pharmaceuticals, our second partner, and became a publicly traded company with an upsized offering. We also presented the first in vivo CRISPR liver editing data, and significantly grew our capabilities, laboratories, and team," said Nessan Bermingham, Ph.D., chief executive officer and founder, Intellia Therapeutics. "I am extremely pleased with the progress since forming the company in May 2014. In 2017, we expect to make meaningful steps toward our goal of bringing revolutionary therapies to patients."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]